ClinicalTrials.gg
RecruitingNCT06754371Updated Mar 17, 2025

Prophylactic Tranexamic Acid Reduces Postpartum Hemorrhage

A Phase 4 interventional study of tranexamic acid and normal saline in Postpartum Hemorrhage and Systemic Autoimmune Diseases, sponsored by RenJi Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by RenJi Hospital · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies testing Tranexamic Acid in Postpartum Hemorrhage — 8 open to participants now, 8 under way, 3 of them phase 3. Tranexamic Acid · Postpartum Hemorrhage.

Planned enrollment
20th of 50
276 · median 198
Started
2025
with 1 other
Phase 4
11 of 50
1 open now
Registered
46th of 50
by date

Among the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, this one is the 20th largest by planned enrollment, is one of 2 that started in 2025, is one of 11 in phase 4, and was the 46th registered.

Postpartum Hemorrhage

471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

8 of the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage are open now, in 8 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, or all of them as a file.
02

Study summary

Postpartum hemorrhage (PPH) is the most significant leading cause of pregnancy-related mortality in high-risk cesarean delivery women. Systemic autoimmune diseases are associated with adverse pregnancy outcomes (APOs), including PPH, preeclampsia, thromboembolism, abortion, and intrauterine growth restriction. The incidence of PPH in women with systemic lupus erythematosus has been reported to be as high as 34%. Prevention of PPH is the key to reduce complications in high-risk women. In recent years, a large number of clinical studies have confirmed that the early preventive use of tranexamic acid(TXA) can reduce the amount of blood loss, the need for additional uterine contraction agents, the risk of blood transfusion, and maternal adverse outcomes, and do not increase the risk of thromboembolic events, which can be used to prevent PPH. However, the study population of TXA is mainly low-risk puerpera, and there is still a lack of relevant research on TXA used in pregnant women with systemic autoimmune diseases. The purpose of this study was to evaluate the safety and efficacy of TXA in preventing postpartum hemorrhage after cesarean delivery in women with systemic autoimmune disease, as well as the maternal and neonatal risks associated with systemic autoimmune disease, to provide evidence for clinical practice and further research.

Read the detailed description

The worldwide estimated cumulative prevalence of autoimmune disease is approximately 5%. Studies are often limited by small sample sizes and focused on a specific autoimmune disease such as systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), which is characterized by the production of autoantibodies leading to inflammation of multiple organs. Systemic autoimmune diseases are associated with adverse pregnancy outcomes (APOs), including increased cesarean delivery rates, PPH, preeclampsia, thromboembolism, abortion, premature delivery, and intrauterine growth restriction. Preeclampsia is the most commonly reported complication in patients with SLE and is also a high risk factor for PPH. The incidence of PPH in women with SLE has been reported to be as high as 34%. PPH increases the need for blood transfusion and related complications and is a significant clinical and socio-economic problem. Therefore, prevention of PPH is the key to reduce the postpartum complications of high-risk women. At present, the methods commonly used to prevent PPH after cesarean delivery include uterine massage, prophylactic use of uterine contraction agents in the third stage of labor, and early use of TXA. Recent clinical studies of TXA use in high-risk cesarean delivery women have shown that prophylactic use of TXA significantly reduces blood loss, prevents PPH, and reduces ICU admission and length of stay. There was no evidence of an increased risk of maternal-related complications with TXA use. But there is still a lack of relevant research on TXA used in pregnant women with systemic autoimmune diseases. Anti-phospholipid antibodies (aPL) are often present in SLE and APS patients, which predict serious perinatal complications and are associated with the risk of thrombosis. aPL are detected not only in SLE and APS but also in other connective tissue diseases such as systemic sclerosis (SSc), Sjögren's syndrome (SS), rheumatoid arthritis (RA), and undifferentiated connective tissue disease (UCTD). Although TXA has been widely used in patients at high risk for thromboembolism, such as trauma, orthopedics, and cardiac surgery in recent years, the evidence strongly supports that it does not increase the risk of death or thromboembolic complications. More evidence from high quality randomized controlled trials is needed to assess the benefits and risks of its use in women at high risk of PPH after cesarean delivery.

The aim of this study was to evaluate the safety and efficacy of TXA in preventing PPH after cesarean delivery in women with systemic autoimmune disease. Patients undergoing cesarean delivery were randomly assigned to TXA group(intravenous infusion of TXA 1g (20ml) 10min before skin dissection) and placebo group(intravenous infusion of normal saline 20ml 10min before skin dissection).The estimated blood loss 24h postoperatively, blood transfusion 3d postpartum, additional uterotonics, other surgical intervention for PPH and thromboembolic events were recorded.

03

Conditions studied

  • Postpartum Hemorrhage
  • Systemic Autoimmune Diseases

Keywords

  • postpartum hemorrhage
  • systemic autoimmune disease
  • cesarean delivery
  • thromboembolism
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients undergoing cesarean delivery
  2. Preoperative diagnosis of pregnancy with systemic diseases (systemic lupus erythematosus, antiphospholipid syndrome, systemic sclerosis, Sjogren's syndrome, rheumatoid arthritis, undifferentiated connective tissue disease)
  3. Obtain .

Exclusion criteria

Exclusion Criteria:

  1. intrauterine fetal death
  2. Existing/previous history of thromboembolism
  3. Hemorrhagic disease, significant prenatal bleeding
  4. Balloon placement of internal iliac artery
  5. Allergic to tranexamic acid
  6. Severe renal insufficiency (serum creatinine >451μmol/L or blood urea nitrogen >20mmol/L)
  7. Epilepsy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
276 participants (estimated)

Study arms

  • Experimental
    Tranexamic acid group

    intravenous infusion of tranexamic acid 1g (20ml) 10min before skin dissection

    Drug: tranexamic acid

  • Placebo comparator
    Placebo group

    intravenous infusion of normal saline 20ml 10min before skin dissection

    Drug: normal saline

Interventions

  • intravenous infusion of tranexamic acid 1g (20ml) 10min before skin dissection

    Also known as: TXA

  • Drugnormal saline

    intravenous infusion of normal saline 20ml 10min before skin dissection

06

What researchers measure

Primary outcomes

  1. The incidence of postpartum hemorrhage

    Postpartum hemorrhage is defined as blood loss of 1000 mL or more within the first 24 h after cesarean delivery.

    Time frame: From skin incision to 1day after surgery

  2. Estimated blood loss within 1day after surgery

    Estimated blood loss is calculated by GROSS EQUATION: Estimated Blood Loss (EBL) = EBV ×((HCT1 - HCT2)/(HCT mean)), EBV = Estimated Blood volume; whereas EBV = Patient's weight (in kilogram) × 70 mL/kg, HCT1=preoperative hematocrit, HCT2 = postoperative hematocrit, and HCT mean = (HCT1 + HCT2)/2;

    Time frame: From skin incision to 1day after surgery

Secondary outcomes

  1. The volume of blood transfusion within 3days after surgery and complications

    The volume of blood transfusion within 3days after surgery and complications(such as fever, allergy, hemolysis, renal dysfunction,etc)

    Time frame: From skin incision to 3days after surgery

  2. Whether additional uterotonics are needed

    Uterotonics other than intraoperative routine dose intravenous and intrauterine infusion of oxytocin.

    Time frame: From the delivery of placenta until 3 days postoperatively

  3. Whether other surgical intervention for PPH are needed

    Patients who need other surgical intervention(such as intrauterine balloon compression hemostasis, uterine artery ligation or embolization and hysterectomy) to control PPH

    Time frame: From the delivery of placenta until 3 days postoperatively

  4. Incidence of thromboembolic events

    The occurrence of thromboembolic events within one week of delivery, including deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke

    Time frame: Patients will be followed up to one week after surgery

  5. Maternal complications

    Occurrence of adverse effects (nausea, vomiting, headache, epilepsy, renal impairment,coagulopathy) within 3days after surgery.

    Time frame: Patients will be followed up to 3days after surgery

  6. Maternal and neonatal 3 months mortality

    All-cause 3 months mortality

    Time frame: Patients and neonates will be followed up to 3 months after surgery

  7. Estimated intraoperative blood loss

    Estimated intraoperative blood loss is calculated using the formula: collected blood volume in the suction canister (ml)-the volume of amniotic fluid (ml)-the volume of flushing (ml) + the volume from the gauze tampon (ml)

    Time frame: From skin incision to the end of the surgery

07

Study locations

1 of 1 sites recruiting
  • Renji Hospital, Shanghai Jiaotong University, School of Medcine
    Shanghai, Shanghai, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 24 months after the start.

Of 28 non-industry phase 4 interventional studies under Postpartum Hemorrhage, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's planned 24 months is above that.

Counting every sponsor, half of 29 studies reached it within 12 months; a quarter within 10 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2024
First posted
Dec 31, 2024
StartActual
Jan 6, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jun 2027
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06754371
Lead sponsor
RenJi Hospital
Responsible party
Sponsor
First posted
Dec 31, 2024
Start date
Jan 6, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Mar 17, 2025

Study contacts

Jie Xiao, PHD
Contact
applexiaomz@163.com
+13817931390
Jie Xiao, PHD
study director · Renji Hospital, Shanghai Jiaotong University, School of Medcine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion